Nexalin enrolls first patients, advances toward treatment in UCSD trial

Nexalin Technology (NXL) announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego, UCSD, in collaboration with the VA San Diego Healthcare System. The company began treatment of the first patients this week with the Nexalin HALO. This significant milestone marks the transition from patient recruitment to active participation in the study, which aims to evaluate Nexalin’s proprietary Deep Intracranial Frequency Stimulation technology, delivered through its HALO Clarity devices, as a potential treatment for mild traumatic brain injury and post-traumatic stress disorder in military personnel and the civilian population. The collaboration with UCSD and the San Diego VA underscores Nexalin’s commitment to advancing breakthrough treatment options for patients who are underserved by current therapies.